NTRB Stock Analysis: Buy, Sell, or Hold?
NTRB - Nutriband Inc. Common Stock
$3.46
-0.40 (-10.36%)
▼
5d:
-9.9%
30d:
-22.07%
90d:
-27.92%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: Apr 27, 2026
26d
Get Alerted When NTRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NTRB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NTRB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.89
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$3.66
5.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NTRB is currently trading at $3.46, which is considered oversold relative to its 30-day fair value range of $3.77 to $4.32. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.4) compared to its historical average (2.9). Remarkably, the market is currently pricing in an annual earnings decline of 6.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NTRB is in a strong downtrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+333.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NTRB is in a strong downtrend. The price is currently testing key support at $3.42. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.4% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.00 (+333.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.77 -
$4.32
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.4%)
- BULLISH: Trading 333.5% below Wall St target ($15.00)
- CAUTION: Recommendation downgraded due to -9.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$3.77 -
$4.32
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.08
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.39
Wall Street Target
$15.00
(+333.5%)
Revenue Growth (YoY)
-46.4%
Valuation Discount vs History
-6.7% cheaper
PE vs Historical
2.4 vs 2.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.7%
(market-implied from PE analysis)
1-Year Target
$3.23
(-7%)
2-Year Target
$3.01
(-13%)
3-Year Target
$2.81
(-19%)
3-Yr Target (if PE normalizes)
(PE: 2→3)
$3.42
(-1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.4 to 2.9
Stabilization Target:
$4.20
(+21.5%)
PE Expansion Potential:
+21.5%
Share & Embed Analysis
Last updated: March 31, 2026 5:39 AM ET
Data refreshes hourly during market hours. Next update: 6:39 AM
Data refreshes hourly during market hours. Next update: 6:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 63 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$873 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$224 | 57 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$100 | 59 HOLD |
